STAMFORD, Conn., Sept. 30, 2024 – Purdue Pharma has completed the first phase of a study examining the use of nalmefene hydrochloride (HCI) injection in real-world emergency department (ED) settings. Researchers are now conducting data analysis, with...
STAMFORD, Conn., August 7, 2024 – Purdue Pharma L.P. (“Purdue”) announced today that the U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the Zurnai™ (nalmefene injection) Auto-Injector. Zurnai (zur nye) is a single-dose...
STAMFORD, Conn., May 06, 2024 – Purdue Pharma L.P. (“Purdue”) announced today that the company has partnered with MMCAP Infuse to provide buprenorphine and naloxone tablets CIII (generic Suboxone®), a medication for opioid use disorder (“MOUD”), at low cost to...
STAMFORD, Conn., April 08, 2024 – Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*. If the auto-injector is approved, it...
STAMFORD, Conn., March 27, 2024 – Purdue Pharma L.P. (“Purdue”) announced today that the Company has awarded an investigator-initiated research (IIR) grant to a team of researchers at The University of New Mexico (UNM) for the evaluation of nalmefene hydrochloride...
Please read carefully the Purdue Pharma L.P. Privacy Policy (the “Privacy Policy”), which is part of the Purdue Pharma L.P. Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parties’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through Your use of the Service, how we use it, how we share it, how we protect it, and the choices You can make about Your information.
